<DOC>
	<DOC>NCT01163292</DOC>
	<brief_summary>The present survey was conducted to evaluate the effectiveness and safety of treatment with adalimumab during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-859) in participants who continued treatment with adalimumab for 52 weeks.</brief_summary>
	<brief_title>Special Investigation (Follow up Survey of the Study of Adalimumab (D2E7)for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859(NCT00870467)</brief_title>
	<detailed_description>This survey was conducted to assess the risk and benefit of continuing or discontinuing biological therapy with adalimumab (Humira) during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-859).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>The participants were patients who continued treatment with adalimumab until the end of the treatment period in the NCT00870467(M06859) study and provided informed consent to participate in the present followup survey. Participants who used biological agents other than adalimumab after the period of treatment in the NCT00870467(M06859) study were excluded from the present followup study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>